<DOC>
	<DOC>NCT00388973</DOC>
	<brief_summary>The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Male or female patients, 66 years or older, with a documented clinical diagnosis of MDD. The presence of dementia or mental disorder other than MDD within 6 months of enrolment, Uncontrolled hypertension, substance or alcohol abuse A current diagnosis of cancer or a current or past diagnosis of stroke</criteria>
	<gender>All</gender>
	<minimum_age>66 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
</DOC>